Target intelligence / Profile preview

Protein geranylgeranyltransferase type I (GGTase-I)

Target
GGTase-I
Molecular classification
Enzyme, Transferase, Protein prenyltransferase
01

Overview

Protein geranylgeranyltransferase type I (GGTase-I) is a cytosolic enzyme that catalyzes the transfer of a 20-carbon geranylgeranyl group from geranylgeranyl diphosphate (GGPP) to a cysteine residue within the C-terminal CaaX motif of substrate proteins, most notably many regulatory GTP-binding proteins. This posttranslational modification, known as geranylgeranylation, facilitates the association of the target proteins with cellular membranes and is essential for their correct localization and function in processes such as signal transduction, proliferation, and cytoskeletal organization. GGTase-I is a heterodimeric enzyme, sharing an alpha subunit with farnesyltransferase but possessing a specific beta subunit that confers substrate specificity for GGPP over FPP. The enzyme is of significant pharmacological interest for anti-cancer and anti-parasitic drug discovery due to its role in modifying proteins critical for cell growth and oncogenesis[1][3][5].

Other names
Geranylgeranyltransferase type IGGTase-ICaaX geranylgeranyltransferaseProtein GG transferase type I
02

Mechanism of action

Inhibition of protein geranylgeranylation (drugs block the enzyme’s ability to transfer geranylgeranyl groups to the CaaX motif of protein substrates, impeding their membrane localization and activity, especially of signaling GTPases such as RhoA, Rac1, and others)[1][3][5]

03

Biological functions

Protein prenylation (posttranslational modification)Membrane targeting of proteinsSignal transductionCell proliferationCell differentiation
04

Disease associations

CancerOther (potentially involved in parasitic diseases, based on anti-parasite drug development)
05

Safety considerations

Potential for off-target effects (due to involvement in posttranslational modification of >100 proteins)Toxicity due to interfering with essential protein localization and functionPossible disruption of normal cell signaling and homeostasis
06

Interacting drugs

GGTI-2133 (experimental inhibitor)

2 more in the full profile.

07

Biomarkers

Prenylated proteins (such as Rho family GTPases, can indicate successful enzyme activity/inhibition)Non-prenylated protein substrates in cells (e.g., accumulation of unmodified RhoA) after GGTase-I inhibitionGene/protein expression changes in prenylation pathways (potential pharmacodynamic biomarkers)

Beyond the preview

Go deeper on Protein geranylgeranyltransferase type I (GGTase-I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein geranylgeranyltransferase type I (GGTase-I).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call